A phase I feasibility study of an intraprostatic prostate-specific antigen-based vaccine in patients with prostate cancer with local failure after radiation therapy or clinical progression on androgen-deprivation therapy in the absence of local definitive therapy

Clin Genitourin Cancer. 2006 Jun;5(1):89-92. doi: 10.3816/CGC.2006.n.024.
No abstract available

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Cancer Vaccines / administration & dosage*
  • Clinical Trials, Phase I as Topic
  • Feasibility Studies
  • Fowlpox virus
  • Genetic Vectors
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
  • Humans
  • Injections, Intralesional
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / radiotherapy
  • Recombinant Proteins
  • Vaccines, Synthetic / administration & dosage*
  • Vaccinia virus

Substances

  • Cancer Vaccines
  • Recombinant Proteins
  • Vaccines, Synthetic
  • rF-TRICOM vaccine
  • Granulocyte-Macrophage Colony-Stimulating Factor